Navigation Links
Anti-cancer drug may treat muscular dystrophy

Recent studies on mice reveal that a drug, being tested as an anticancer agent to treat breast cancer, supports recovery from muscular dystrophy//, a disease that has no cure.

Duchene muscular dystrophy is a disease characterized by progressive weakness and degeneration of the muscles that control movement. According to earlier studies, the functional decline of "dystrophic" muscles can be slowed down by agents that enhance muscle fiber size.

The recent study conducted by Dr. P. L. Puri, from The Burnham Institute in La Jolla, California, and colleagues is published on line yesterday in the journal Nature Medicine. According to this study, the anticancer drug trichostatin A or TSA increases muscles fiber size in two mouse models of muscular dystrophy. Mice with this disability, when given TSA for 3 months, were able to run on treadmills and swim as long as healthy mice. According to the researchers, the drug caused no obvious side effects or signs of toxicity. TSA belongs to a class of drugs called deacetylase inhibitors.

The dystrophic muscles became resistant to contraction-related degeneration when treated with trichostatin A and this is linked with functional and morphological recovery. "We have identified a new rationale for treating muscular dystrophy, aimed at correcting the devastating effects of a single flawed gene," Dr Lorenzo Puri said in a statement. "In the window of time that we have analysed these mice, they seem to perform like normal mice. All the decreases in muscle performance were restored by the treatment. "This is a significant advance over the use of steroid -- currently the only treatment available -- which offers palliative relief, often with severe side effects," he said.

Ms Sharon Hesterlee, a vice-president of the association, which helped finance the research, said "I am hesitant to call the finding a breakthrough, because that could raise expectations unfairly, but it's certainly an i mportant finding."

Puri said, "Extensive investigation is now required to determine if these animal findings also apply to humans with muscular dystrophy. It is difficult to predict how long it will take before these studies will be translated into therapies for human patients," he added. "The next step is to test TSA on larger animals, such as golden retrievers, which contract a form of muscular dystrophy more similar to that in humans, " Dr Puri said.

One in every 3,500 male births is affected by this inherited disease. According to the Muscular Dystrophy Association, 40,000-60,000 people in the US have some form of the inherited disease.
GYT
'"/>




Related medicine news :

1. An Anti-cancer Smart Bomb delivered using a Nanocell
2. Gene Study Offers Hope of Potent Anti-cancer Drugs
3. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
4. Thyroid hormone treatment hastens recovery after cardiac surgery
5. Feeding channel created by malaria parasite - a new target for malaria treatments
6. New drug to treat Heart Attack and damaged tissue
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture of saliva ... teeth," said an inventor from Bridgewater, N.J. "I thought that there had to be ... , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a ... opening of a new residential mental health treatment program in Chino Hills, California.  The ... as severe anxiety, depression, bi-polar disorder, and other related issues. , Center For ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
(Date:11/30/2016)... ... , ... BrightStar Care of Wellington , a home care agency that ... 2016 Provider and Employer of Choice by Home Care Pulse. The Best of Home ... with the highest quality receive the Best of Home Care Award from Home Care ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... , , Drug delivery ... value of drug delivery technologies and the anticancer drugs are difficult ... organs involved and the types of cancer as well as according ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories (das "Unternehmen"), ... diesem Monat seinen  INSTI HIV-Selbsttests  in einer Version mit geringeren Kosten einzuführen.  ... ... New: INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Detachable Coils 2017 - MedCore" report to their offering. ... , , ... and cerebral blood vessel malformations. The detachable coil embolization treatment of cerebral ... An aneurysm is a weakened area in the wall of an artery ...
Breaking Medicine Technology: